Ranjana H. Advani, MD, on Hodgkin Lymphoma: New Management Options

2017 NCCN Hematologic Malignancies Congress
Tweet this page

Ranjana H. Advani, MD, of Stanford Cancer Institute, discusses the novel immunomodulatory agents used to manage patients with relapsed or refractory Hodgkin lymphoma.

Advertisement

Advertisement



Advertisement